These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9285228)

  • 1. Saving future lives. A comparison of three discounting models.
    Cairns JA; van der Pol MM
    Health Econ; 1997; 6(4):341-50. PubMed ID: 9285228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constant and decreasing timing aversion for saving lives.
    Cairns J; van der Pol M
    Soc Sci Med; 1997 Dec; 45(11):1653-9. PubMed ID: 9428085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the discounting of gained life-years in cost-effectiveness analysis.
    Johannesson M
    Int J Technol Assess Health Care; 1992; 8(2):359-64. PubMed ID: 1628916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discounting in the economic evaluation of health care interventions.
    Krahn M; Gafni A
    Med Care; 1993 May; 31(5):403-18. PubMed ID: 8501989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discounting in cost-effectiveness research.
    Ganiats TG
    Med Decis Making; 1994; 14(3):298-300; discussion 301-3. PubMed ID: 7934717
    [No Abstract]   [Full Text] [Related]  

  • 6. Double discounting of QALYs.
    MacKeigan LD; Gafni A; O'Brien BJ
    Health Econ; 2003 Feb; 12(2):165-9. PubMed ID: 12563665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multilevel models and health economics.
    Rice N; Jones A
    Health Econ; 1997; 6(6):561-75. PubMed ID: 9466139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discounting in health care decision-making: time for a change?
    Sheldon TA
    J Public Health Med; 1992 Sep; 14(3):250-6. PubMed ID: 1419202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discounting life-years: whither time preference?
    Gyrd-Hansen D; Søgaard J
    Health Econ; 1998 Mar; 7(2):121-7. PubMed ID: 9565168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time preference for health gains versus health losses.
    MacKeigan LD; Larson LN; Draugalis JR; Bootman JL; Burns LR
    Pharmacoeconomics; 1993 May; 3(5):374-86. PubMed ID: 10146888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Willingness to pay methods in health care: a sceptical view.
    Cookson R
    Health Econ; 2003 Nov; 12(11):891-4. PubMed ID: 14601152
    [No Abstract]   [Full Text] [Related]  

  • 12. Time preferences for health in northern Tanzania: an empirical analysis of alternative discounting models.
    Robberstad B; Cairns J
    Pharmacoeconomics; 2007; 25(1):73-88. PubMed ID: 17192119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Environmental regulation, cost-benefit analysis, and the discounting of human lives.
    Revesz RL
    Columbia Law Rev; 1999 May; 99(4):941-1017. PubMed ID: 10558577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contingent valuation method in health care. An economic evaluation of Alzheimer's disease.
    Nocera S; Telser H; Bonato D
    Dev Health Econ Public Policy; 2003; 8():iii-xi, 1-116. PubMed ID: 15027158
    [No Abstract]   [Full Text] [Related]  

  • 15. Weighing outcomes by time or against time? Evaluation rules in intertemporal choice.
    Scholten M; Read D; Sanborn A
    Cogn Sci; 2014 Apr; 38(3):399-438. PubMed ID: 24404941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical issues in cost-effectiveness analyses.
    Thompson S
    Stat Methods Med Res; 2002 Dec; 11(6):453-4. PubMed ID: 12516983
    [No Abstract]   [Full Text] [Related]  

  • 17. On discounting of health gains from human papillomavirus vaccination: effects of different approaches.
    Westra TA; Parouty M; Brouwer WB; Beutels PH; Rogoza RM; Rozenbaum MH; Daemen T; Wilschut JC; Boersma C; Postma MJ
    Value Health; 2012 May; 15(3):562-7. PubMed ID: 22583467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios'.
    Briggs A; Fenn P
    Health Econ; 1997; 6(5):491-5. PubMed ID: 9353649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group.
    Weinstein MC; Siegel JE; Garber AM; Lipscomb J; Luce BR; Manning WG; Torrance GW
    Health Econ; 1997; 6(5):505-10. PubMed ID: 9353651
    [No Abstract]   [Full Text] [Related]  

  • 20. A proposed model for conducting institutional-specific cost-effectiveness analysis: a case study of lipid-lowering agents.
    Hakim Z; Pierson JF; Pathak DS
    Pharm Pract Manag Q; 1996 Apr; 16(1):79-97. PubMed ID: 10157744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.